.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Argus Health
US Department of Justice
Boehringer Ingelheim
Moodys
Chinese Patent Office
McKinsey
Julphar
Farmers Insurance
Johnson and Johnson

Generated: July 26, 2017

DrugPatentWatch Database Preview

Carbidopa; levodopa - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for carbidopa; levodopa and what is the scope of carbidopa; levodopa patent protection?

Carbidopa; levodopa
is the generic ingredient in seven branded drugs marketed by Mayne Pharma, Impax Labs Inc, Apotex, Apotex Inc, Idt Australia Ltd, Impax Labs, Accord Hlthcare, Mylan, Sun Pharm Inds, Ranbaxy, Abbvie Inc, Merck Sharp Dohme, Actavis Elizabeth, Kv Pharm, SCS, Watson Labs, Sun Pharma Global, and Ucb Inc, and is included in twenty-nine NDAs. There are nine patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Carbidopa; levodopa has thirty-three patent family members in thirteen countries.

There are eighteen drug master file entries for carbidopa; levodopa. Thirty-one suppliers are listed for this compound.

Summary for Generic Name: carbidopa; levodopa

Tradenames:7
Patents:9
Applicants:18
NDAs:29
Drug Master File Entries: see list18
Suppliers / Packagers: see list31
Clinical Trials: see list337
Therapeutic Class:Antiparkinson Agents
Drug Prices:see low prices
DailyMed Link:carbidopa; levodopa at DailyMed

Pharmacology for Ingredient: carbidopa; levodopa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc
RYTARY
carbidopa; levodopa
CAPSULE, EXTENDED RELEASE;ORAL203312-004Jan 7, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Mylan
CARBIDOPA AND LEVODOPA
carbidopa; levodopa
TABLET, EXTENDED RELEASE;ORAL075091-001Sep 30, 1999ABRXNoNo► Subscribe► Subscribe► Subscribe
Actavis Elizabeth
CARBIDOPA AND LEVODOPA
carbidopa; levodopa
TABLET;ORAL074260-002Sep 3, 1993ABRXNoNo► Subscribe► Subscribe► Subscribe
Scs
CARBIDOPA AND LEVODOPA
carbidopa; levodopa
TABLET;ORAL074080-003Mar 25, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Impax Labs Inc
RYTARY
carbidopa; levodopa
CAPSULE, EXTENDED RELEASE;ORAL203312-004Jan 7, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: carbidopa; levodopa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
SINEMET
carbidopa; levodopa
TABLET;ORAL017555-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Merck Sharp Dohme
SINEMET
carbidopa; levodopa
TABLET;ORAL017555-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Merck Sharp Dohme
SINEMET CR
carbidopa; levodopa
TABLET, EXTENDED RELEASE;ORAL019856-002Dec 24, 1992► Subscribe► Subscribe
Merck Sharp Dohme
SINEMET CR
carbidopa; levodopa
TABLET, EXTENDED RELEASE;ORAL019856-001May 30, 1991► Subscribe► Subscribe
Merck Sharp Dohme
SINEMET
carbidopa; levodopa
TABLET;ORAL017555-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: carbidopa; levodopa

Country Document Number Estimated Expiration
Japan2017014295► Subscribe
European Patent Office1507518► Subscribe
China101910113► Subscribe
Canada2486859► Subscribe
Japan2005528430► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Express Scripts
QuintilesIMS
AstraZeneca
Fuji
Covington
Cipla
Harvard Business School
US Army
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot